Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis

Am J Ophthalmol. 2000 Aug;130(2):242-3. doi: 10.1016/s0002-9394(00)00495-5.

Abstract

Purpose: To report two cases in which a bull's eye maculopathy developed after intravitreal injection of fomivirsen.

Methods: Case reports.

Results: A 50-year-old man with acquired immunodeficiency syndrome (AIDS) and refractory cytomegalovirus retinitis developed bull's-eye pigmentary changes in the macula of the right eye after initiating therapy with fomivirsen (Vitravene; CIBA Vision, Atlanta, Georgia) intravitreal injections. These pigmentary changes resolved upon cessation of treatment. A 36-year-old man with AIDS and refractory bilateral cytomegalovirus retinitis developed bull's-eye pigmentary changes in both eyes during bilateral intravitreal treatment with fomivirsen. Vision was not affected. These changes resolved after treatment with fomivirsen was stopped.

Conclusion: Fomivirsen, a new medication for the treatment of refractory cytomegalovirus retinitis, may cause a bull's-eye maculopathy in some patients. The bull's-eye maculopathy is reversible and does not appear to affect vision.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • Adult
  • Antiviral Agents / adverse effects*
  • Antiviral Agents / therapeutic use
  • Cytomegalovirus Retinitis / drug therapy*
  • Humans
  • Injections
  • Macula Lutea / drug effects*
  • Macula Lutea / physiopathology
  • Male
  • Middle Aged
  • Retinal Diseases / chemically induced*
  • Retinal Diseases / physiopathology
  • Thionucleotides / adverse effects*
  • Thionucleotides / therapeutic use
  • Visual Acuity
  • Vitreous Body

Substances

  • Antiviral Agents
  • Thionucleotides
  • fomivirsen